medicalxpress.com
A new study by researchers at Northwestern University has uncovered a promising strategy to improve the efficacy and durability of mRNA vaccines. Researchers, led by Dr. Pablo Penaloza-MacMaster, found that delaying the administration of costimulatory antibodies until four days after an mRNA vaccination significantly enhanced immune responses in mice. Published in The Journal of Clinical Investigation, these findings could inform the development of improved vaccines for diseases such as HIV, COVID-19, and certain cancers.
Why Timing Matters in Immune Activation
T-cell activation, an essential step for robust immune responses, requires two signals: antigen recognition and costimulation. Previous attempts to enhance T-cell responses by providing these signals simultaneously have largely failed. Dr. Penaloza-MacMaster compared the process to starting a car: "You need to turn on the key [antigen recognition] and let the car warm up before pressing the gas pedal [costimulation]."
In their study, the researchers tested whether delaying the costimulatory antibody treatment targeting the 4-1BB pathway would improve immune responses. The 4-1BB pathway, known to activate T-cells, has been previously studied in cancer immunotherapy and autoimmune disease treatments. The team found that delivering the antibody four days post-vaccination, rather than concurrently, significantly boosted CD8 T-cell activation and enhanced immune durability.
Potential Breakthroughs in Vaccine Development
Delaying the antibody treatment improved immune responses across multiple mRNA vaccines, including those targeting SARS-CoV-2, HIV, and cancer. Mice that received the delayed treatment exhibited better infection clearance and longer-lasting immunity compared to those who received simultaneous treatment. These results challenge the traditional immunological view that antigen recognition and costimulation must occur simultaneously, suggesting that staggered timing of these signals can optimize immune activation.
This delayed approach also showed promise in cancer vaccine models, where treated mice displayed greater efficacy in fighting tumors. The findings highlight the potential of timing-based strategies to improve the effectiveness of vaccines against a range of challenging diseases.
Why This Matters to Healthcare
While current mRNA vaccines are highly effective at reducing severe infections and mortality, they often require multiple boosters to maintain efficacy. Their limited durability and susceptibility to breakthrough infections underscore the need for improved vaccine strategies. Delayed antibody treatment could extend vaccine longevity, reduce booster dependence, and enhance protection against infectious diseases and cancers.
As researchers continue to refine mRNA technology, this approach could represent a significant step forward, paving the way for more durable and effective vaccines in the fight against global health challenges.